Reactions 1680, p3 - 2 Dec 2017 Limbrel capsules linked with serious AEs in the US The US FDA is advising consumers not to use the flavonoid-containing capsules (Limbrel) while the products are under investigation due to the risk of serious adverse events (AEs). In the US, Limbrel capsules are marketed by Primus Pharmaceuticals as a medical food to manage the metabolic processes associated with osteoarthritis. The products are available in two dosages (as Limbrel250 and Limbrel500) and contain two types of flavonoids: baicalin (from Scutellaria baicalensis; a species of flowering plant also known as Chinese skullcap) and catechin (from Acacia catechu – an extract of acacia trees that is used as a food additive, astringent, tannin, and dye). While a range of AEs have been reported with these products, "two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis", noted the FDA. In total, the agency has received a total of 194 Limbrel- associated AEs, of which there was sufficient information in 57 cases to determine if Limbrel was associated with the reported AE. In 30 of those cases, there was sufficient information for FDA medical experts to determine that Limbrel was likely associated with these AEs. The agency is continuing to investigate Primus Pharmaceuticals and the Limbrel manufacturing processes, and further information regarding Limbrel- related AEs and the product formulation have been requested. In the meantime, people consuming this product are advised to immediately stop taking it and contact their doctor. Both consumers and healthcare professionals are also encouraged to report any AEs associated with the Limbrel products via the FDA’s MedWatch programme. US Food and Drug Administration. Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory - Linked to Potentially Life-Threatening Health Problems. Internet Document : 21 Nov 2017. Available from: URL: https://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ ucm586111.htm 803285959 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera